Fig. 2
Antitumoral activity of combined AduPARE1A plus gemcitabine treatment in BxPC-3-Luc and PANC-1-Luc orthotopic tumors. a Schematic representation of treatment protocols applied in mice bearing BxPC-3 and PANC-1 orthotopic tumors. BxPC-3-Luc and PANC-1-Luc orthotopic tumors were treated with a weekly dose of 160 mg/kg of gemcitabine for 3 weeks (T1), with a single dose of AduPARE1A (5 × 1010 vp) (T2), with the combined treatment, replacing a dose of gemcitabine for the AduPARE1A (T3), or with saline in the control group. b Luciferase quantification of bioluminescent emission images from BxPC-3-Luc and PANC-1-Luc tumor-bearing mice, at different time points. Bars graph represent luciferase quantification at 21 and 35 days after treatment in BxPC-3 and PANC-1, respectively. Results are expressed as photons per second. Values are represented as mean ± SEM). (*p < 0.05; **p > 0.01; ***p < 0.001). c Kaplan-Meier survival curves in BxPC-3-Luc tumors: (T1: log rank test = 0.003, T2: log rank test = 0.001, T3: log rank test = 0.0001); in PANC-1-Luc tumors (T1: log rank test = 0.014, T2: log rank test = 0.0002, T3: log rank test = 0.0006). BxPC-3-Luc xenografts: saline: n = 8; Gem: n = 9; AduPARE1A n = 6; combined: n = 8. PANC-1-Luc xenografts: saline: n = 7; Gem: n = 6; AduPARE1A n = 7; combined n = 6